

Eggert, et al. Influence of the non-ergot dopamine agonist piribedil on vigilance in patients with parkinson's disease and excessive daytime sleepiness (PIVICOG-PD). *Clinical Neuropharmacology* 37 (4), 116-22, 2014.

Ehret R, et al. Langzeitwirkung von Piribedil auf Motorik und Vigilanz. *Psychopharmakotherapie* 21, 150-2, 2014.

De Mey C, et al. Bioequivalence of a novel minitablet formulation of levetiracetam. *Arzneim.-Forsch./Drug Research* 62, 94-98, 2012.

Ries S, et al. Levetiracetam-Minitabletten fördern die Compliance bei Epilepsiepatienten. *Psychopharmakotherapie* 19 (6), 260-64, 2012.

Steinhoff B, et al. Retardiertes vs. schnell freisetzendes Oxcarbazepin bei therapierefraktärer fokaler Epilepsie – eine offene multizentrische, randomisierte, kontrollierte Studie. *Der Nervenarzt* 10, 1292-99, 2012.

Jost W, et al. Piribedil – ein non-ergot Dopaminagonist mit besonderem Rezeptorprofil. Ergebnisse von 2 Studien bei Patienten mit idiopathischem Parkinsonsyndrom im klinischen Alltag. *Nervenheilkunde* 9, 571-77, 2010.

Steinhoff B. Oxcarbazepine extended release formulation in epilepsy. *Exp Rev Clin Pharmacol* 2 (2), 155-62, 2009.

Wangemann M, et al. In vivo biopharmaceutical characterisation of a new formulation containing the antiepileptic drug lamotrigine in comparison to plain and dispersible/chewable lamotrigine. *Arzneim.-Forsch./Drug Research* 55 (6), 429-435, 2005.

Bast, et al. The influence of sulthiame on EEG in children with benign childhood epilepsy with centrotemporal spikes (BECTS). *Epilepsia* 44 (2), 215-20, 2003.

Debus, et al. Add-on treatment with pyridoxine and sulthiame in 12 infants with West syndrome: an open clinical study. *Seizure* 11, 381-3, 2002.

Rating, et al. Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. *Epilepsia* 41 (10), 1284-88, 2000.

Wangemann M, et al. Study on the dose proportionality of sustained release sodium valproate. *International Journal of Clinical Pharmacology and Therapeutics* 38, 395-401, 2000.

Rating, et al. Sulthiame vs placebo in the treatment of benign epilepsy with centrotemporal spikes (Rolandic epilepsy). *Europ J Paediatric Neurology* 3, Abstract 44, 1999.

Wangemann M, et al. Pharmacokinetic Characteristics of a new multiple unit sustained release formulation of sodium valproate. *International Journal of Clinical Pharmacology and Therapeutics* 37, 100-108, 1999.

Wangemann M, et al. Bioavailability study of two carbamazepine containing sustained release formulations after multiple oral dose administration. *Arzneim.-Forsch./Drug Res.* 48 (II), 12, 1131-7, 1998.

Retzow A, et al. Influence of food on the pharmacokinetics of a new multiple unit sustained release sodium valproate formulation. *Arzneimittelforschung* 47, 1347-1350, 1997.

Wangemann M, et al. Replacement of oral valproate with intravenous valproate: a study on dose finding and bioavailability. *European Journal of Clinical Research* 9:209-215, 1997.

Schulz, et al. Investigation of the bioequivalence of two carbamazepine sustained-release formulations in healthy subjects. *International Journal of Clinical Pharmacology, Therapy and Toxicology* 30, 410-414, 1992.